Close Menu
    Facebook X (Twitter) Instagram
    Facebook Instagram Threads
    Global BiodefenseGlobal Biodefense
    Subscribe
    • Featured News
    • Funding
    • Directory
    • Jobs
    • Events
    Global BiodefenseGlobal Biodefense
    Biosecurity

    HHS Adds New Anthrax Countermeasures to Stockpile

    By Global Biodefense StaffNovember 13, 2015
    Bacillus anthracis mishap
    Share
    Facebook LinkedIn Reddit Email

    The U.S. Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response (ASPR) this week announced it will add two types of anthrax antitoxin drugs to the Strategic National Stockpile (SNS) as options to treat inhalational anthrax.

    ASPR’s Biomedical Advanced Research and Development Authority (BARDA) will fund these purchases under Project BioShield, the chief mechanism through which the U.S. government supports the advanced development and procurement of new medical countermeasures – drugs, vaccines, diagnostics, and medical supplies – to protect the American public against chemical, biological, radiological and nuclear threats.

    “Anthrax remains a bioterrorist threat, and the actions we are taking today will help protect our nation against that threat,” said Robin Robinson, Ph.D., Director of BARDA. “By expanding the treatment options available within the SNS, we can help meet the diverse needs of the American people in an anthrax-related emergency.”

    Elusys Therapeutics – Anthim

    A five-year, $44.9 million agreement with Elusys Therapeutics of Pine Brook, New Jersey, BARDA will support production and future delivery of Elusys’ anthrax antitoxin drug Anthim to the SNS. Anthim is a is a high-affinity monoclonal antibody (mAb) that binds to a key bacterial protein and reduces anthrax’s toxic effects. The antitoxin becomes the fourteenth product to be added to the SNS under Project BioShield since 2004.

    Support for development of Anthim transitioned from early development with the National Institute of Allergy and Infectious Diseases (NIAID) to advanced development with BARDA in 2009. Elusys submitted a Biologics License Application for Anthim to the U.S. Food and Drug Administration (FDA) in March 2015, and BARDA continues to support the drug’s development under a separate research and development contract.

    Prior to licensure, large-scale use of Anthim after an anthrax attack would require Emergency Use Authorization from FDA.

    GlaxoSmithKline – Raxibacumab

    In addition, through a continuing agreement with GlaxoSmithKline BARDA will fund the production and delivery of the anthrax antitoxin drug Raxibacumab to replace expiring doses in the SNS.

    Raxibacumab is also a monoclonal antibody therapeutic to treat illness caused by anthrax. BARDA has funded advanced development and procurement of the drug under Project Bioshield since 2009 and in 2012 Raxibacumab became the first anthrax antitoxin to be approved by the FDA. Now, BARDA will provide $9.7 million to ensure a continued supply of Raxibacumab to the SNS through 2019.

    Source: HHS, adapted.

    Anthrax Antitoxins ASPR Awards BARDA Bioterrorism Emergency Use Authorization HHS Strategic National Stockpile
    Share. Facebook LinkedIn Reddit Email
    Previous ArticleParker Appointed to DHS Science and Technology Advisory Committee
    Next Article Biodefense Headlines – Nov 15, 2015

    Related Stories

    First Light Diagnostics Receives FDA Clearance for Rapid Anthrax Test

    December 5, 2023

    ARPA-H Announces New Tiered Proposal Submission System to Reduce Applicant Barriers

    December 5, 2023

    Needle-Free Vaccine Patch Against Zika Virus

    December 2, 2023

    Ontario Supporting $165M Investment to Secure Critical PPE Supply

    December 2, 2023
    News Scan

    Biodefense Headlines – 30 November 2023

    News Scan November 30, 2023

    News highlights on health security threats and countermeasures curated by Global Biodefense This week’s selections include the largest ever outbreak of mpox in the DRC; launch of National Wastewater Surveillance Program dashboard; low uptake of COVID-19 boosters and flu vaccines;…

    Upcoming Events

    Mar 12
    Hybrid Hybrid Event
    March 12, 2024 - March 17, 2024

    2024 Fungal Genetics Conference

    Mar 21
    March 21, 2024 - March 23, 2024

    ASPPH 2024 Annual Meeting

    View Calendar

    Subscribe to Global Biodefense

    Get the latest news on pathogens and preparedness

    News on pathogens and preparedness for public health emergencies

    © 2023 Stemar Media Group LLC
    • About
    • Contact
    • Privacy
    • Subscribe

    Type above and press Enter to search. Press Esc to cancel.